These drugs are called disease-modifying antirheumatic drugs (DMARDs), and they are an important part of an overall treatment plan. Disease-modifying drugs act on the immune system to slow the progression of rheumatoid arthritis. This is why they are called "disease-modifying." Many different drugs can be used as DMARDs in the treatment of RA, but some are used more often than others. Plaquenil and glaucoma Does hydroxychloroquine cause cancer Chloroquine fas associated How to dissolve chloroquine diphosphate salt Hydroxychloroquine is an antimalarial drug which is relatively safe and well-tolerated agent for the treatment of rheumatoid arthritis. Chloroquine is another antimalarial agent that is also sometimes used. This is sometimes called “triple therapy” and includes methotrexate, hydroxychloroquine Plaquenil, and sulfasalazine. Researchers demonstrated that this triple therapy approach has been shown to be as effective as biologic treatments and is certainly much cheaper. Abatacept Orencia is often prescribed after failure of a disease-modifying anti-rheumatic agent DMARD, like methotrexate but it can be used as first-line therapy. Abatacept is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. They are not as powerful as other DMARDs, but they usually cause fewer side effects. Hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine) are used for mild rheumatoid arthritis. Abatacept sulfasalazine hydroxychloroquine triple therapy DMARDs Arthritis Foundation, Switching Medications Without Waiting too Long RA Chloroquine fluorescence spectrumConcordia pharmaceuticals plaquenilOphthalmology guidelines for plaquenilAti hydroxychloroquine Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis Swefot trial 1-year results of a randomised trial Addition of infliximab compared with addition of.. Abatacept Orencia -. Rheumatoid arthritis - Penn State Hershey Medical Center. Oct 29, 2013 Triple therapy refers to a combination of three non-biologic DMARDs, most frequently sulfasalazine, hydroxychloroquine, and methotrexate. Other DMARDs can be used based on what medications patients can tolerate. Methotrexate-inadequate response In patients with an inadequate response to methotrexate, several treatments were statistically significantly superior to oral methotrexate for ACR50 response triple therapy moderate quality evidence, methotrexate + hydroxychloroquine low quality evidence, methotrexate + leflunomide moderate quality evidence, methotrexate + intramuscular gold very low quality evidence, methotrexate + most biologics moderate to high quality evidence, and. An important and much‐studied group of patients with RA is the group who have had only a partial or a suboptimum response to MTX. A number of studies have enrolled this type of patient and have randomized patients to receive active therapy or placebo in addition to their baseline MTX therapy 9, 11, 13-15.